Using Biologics in the Prevention of Anaphylaxis

Area of Science:

• Immunology
• Allergy and Immunology
• Pharmacology

Background:

• Anaphylaxis management traditionally relies on trigger avoidance and emergency treatment.
• The hypersensitivity reactions can be immediate and life-threatening.

Purpose of the Study:

• To review the emerging role of biologics in preventing anaphylaxis.
• To highlight the new era of biologic therapies for susceptible individuals.

Main Methods:

• Review of current literature on anaphylaxis management and biologic therapies.
• Analysis of immunologic mechanisms driving anaphylaxis.
• Examination of data on omalizumab and other biologics in anaphylaxis prophylaxis.

Main Results:

• Omalizumab is the first approved biologic for preventing food-induced anaphylaxis.
• Knowledge of anaphylaxis immunologic mechanisms is accelerating biologic applications.
• Other biologics targeting IgE, mast cell receptors, cytokines, and alarmins are under investigation.

Conclusions:

• Biologics represent a significant advancement in anaphylaxis prevention.
• Further research into targeted biologic therapies holds promise for managing anaphylaxis.